Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 11:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 843 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo equivalent Clear all

Conditions: Secondhand Smoke, Air Trapping, Tobacco, Airflow Limitation, Hyperinflation, Obstructive Lung Disease
Interventions: Albuterol, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 40 Years to 80 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Seasonal Allergic Rhinitis
Interventions: triamcinolone acetonide aqueous nasal spray (Apotex Inc.), triamcinolone acetonide aqueous nasal spray (Nasacort® AQ), Placebo; Drug
Lead sponsor: Apotex Inc.; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Bedminster, New Jersey

Conditions: Healthy
Interventions: Cannabidiol, Delta-9-THC, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Asthma
Interventions: Beclomethasone dipropionate, Placebo, Albuterol/salbutamol; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 1,113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 94
States / cities: Costa Mesa, California • Huntington Beach, California • Long Beach, California + 77 more

Conditions: Mania (Neurotic)
Interventions: Probio-Tec BG-VCap-6.5, Placebo; Combination Product · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Parkinson, Tremor
Interventions: incobotulinumtoxinA, Saline; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Extreme Prematurity, Intraventricular Hemorrhage, Morbidity;Newborn
Interventions: Indomethacin, Placebo; Drug
Lead sponsor: University of British Columbia; Other
Eligibility: 0 Hours to 12 Hours
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 5
States / cities: Roseville, California • Sacramento, California • Pittsburgh, Pennsylvania + 1 more

Conditions: Post-stroke Shoulder Pain and Spasticity
Interventions: Botulinum Toxin Type A - OnabotulinumtoxinA, Placebo (Saline); Drug
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pain
Interventions: MEB-1170, Placebo; Drug
Lead sponsor: Mebias Discovery, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: HIV-I, Human Immunodeficiency Virus Type 1, Prophylaxis
Interventions: Islatravir, Placebo to FTC/TDF, FTC/TDF, Placebo to ISL; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years to 45 Years · Female only
Enrollment: 730 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 13
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 10 more

Conditions: Deformity; Skin, Fat Redistribution, Lipodystrophy
Interventions: Kybella; Drug
Lead sponsor: The Maas Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Dysfunctional Labor
Interventions: Propranolol, IV Placebo; Drug · Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Metabolism and Nutrition Disorder, Obesity
Interventions: liraglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 27
States / cities: Goodyear, Arizona • Peoria, Arizona • Huntington Beach, California + 22 more

Conditions: Pain
Interventions: ketamine, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 3 Years to 12 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Neoplasms, Prostate
Interventions: dutasteride, placebo, bicalutamide; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 90 Years · Male only
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 47
States / cities: Homewood, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 43 more

Conditions: Advanced Cancers, Dyspnea
Interventions: Fentanyl, Placebo, Walking Tests, Questionnaires; Drug · Other · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Refractory Generalized Myasthenia Gravis
Interventions: Eculizumab, Placebo; Biological · Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 41
States / cities: Birmingham, Alabama • Fresno, California • Los Angeles, California + 35 more

Conditions: Uveitis
Interventions: Sarilumab, Prednisone, Methotrexate, Folic/folinic acid, Placebo (for Sarilumab); Drug · Other
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 5
States / cities: Worcester, Massachusetts • Omaha, Nebraska • Slingerlands, New York + 2 more

Conditions: Asthma
Interventions: Omalizumab, Placebo, Fluticasone; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 628 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 56
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Huntington Beach, California + 48 more

Conditions: PARKINSON DISEASE (Disorder), Advanced Parkinson's Disease
Interventions: SER-252 (PEOZ-apomorphine), enFuse; Drug · Device
Lead sponsor: Serina Therapeutics; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: Englewood, Colorado • Hallandale, Florida • Maitland, Florida + 2 more

Conditions: Pain
Interventions: Buffered Lidocaine J-tip; Drug
Lead sponsor: Phoenix Children's Hospital; Other
Eligibility: Up to 90 Days
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Healthy Volunteers
Interventions: E2511, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Glendale, California

Conditions: Wounds and Injuries, Rib Fractures
Interventions: Ketamine, Placebo, Intercostal Nerve Block, Acetaminophen, Ibuprofen, Pantoprazole, Methocarbamol, Opioid; Drug · Procedure
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Periodontitis, Periodontal Diseases
Interventions: Scaling and root planing, Metronidazole, Amoxicillin, Doxycycline; Procedure · Drug
Lead sponsor: The Forsyth Institute; Other
Eligibility: 20 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Search by objective public record fields.

Secondhand Smoke Respiratory Health Study

A Study Comparing the Bioequivalence of Triamcinolone Acetonide Aqueous Nasal Spray (Apotex, Inc.) to That of Nasacort® AQ Nasal Spray (Sanofi-Aventis Pharmaceutical Products, Inc.) In the Treatment of Seasonal Allergic Rhinitis

The Effects of Cannabidiol and ∆-9-THC in Humans

A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma

A Probiotic Intervention to Prevent Relapse Following Hospitalization for Mania

Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Tremor: A Customized Approach

Single-dose Prophylactic INdomethacin in Extremely Preterm Infants

Randomized DB Controlled Trial of Botulinum Toxin A in Hemiplegic Shoulder Pain and Spasticity

A Study to Assess the Safety of MEB-1170 in Healthy Subjects

Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)

Safety and Efficacy of Deoxycholate Treatment of Small Fatty Deformities ( SFD)

Trial of Oxytocin Alone Versus Oxytocin and Propranolol for the Treatment of Abnormal Labor

Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance

Low Dose Ketamine as an Adjunct to Fentanyl in Outpatient Tonsillectomy

Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy

Breakthrough Dyspnea Fentanyl Study in Cancer Patients

Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)

Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis

Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma

SAD Study in Patients With Parkinson's Disease and Motor Fluctuations

Needle-Free Jet Injection of Lidocaine During Lumbar Puncture

A Study to Assess the Safety and Tolerability of E2511 in Healthy Adult and Elderly Participants

Ketamine Infusion Therapy for the Management of Acute Pain in Adult Rib Fracture Patients

Effect of Three Periodontal Therapies in Current Smokers and Non-Smokers